Articles

According to the IKEMA study interim analysis, isatuximab (Isa) plus carfilzomib and dexamethasone (Isa-Kd) resulted in a clinically meaningful improvement in depth of response; more patients reached minimal residual disease (MRD)-negative status when compared with those patients who received carfilzomib and dexamethasone alone. Read More ›

IKEMA is an ongoing, phase 3, randomized, open-label, parallel-group study that reached its interim analysis milestone. The study evaluated the effect of adding isatuximab (Isa) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

The ongoing GMMG-Concept trial is a phase 2, multicenter, investigator-initiated, open-label trial examining the induction, consolidation, and maintenance treatment of the 4-drug combination of isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients newly diagnosed with high-risk multiple myeloma (MM); this includes both transplant-eligible and non–transplant-eligible patients. Read More ›

The year 2020 was an unprecedented year, bringing significant changes in the practice of medicine and knowledge sharing at scientific forums. National and international meetings, such as the European Hematological Association (EHA) and the American Society of Hematology (ASH), pivoted to facilitate the dissemination of information regarding cutting-edge research and treatment advances in a virtual format. Read More ›

Based on interim results from the STOMP study in patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated, the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates (ORRs) and encouraging progression-free survival (PFS). Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM), preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab show manageable toxicity, moderate efficacy overall, and higher efficacy for those with t(11;14). Read More ›

An ongoing phase 1/2, nonrandomized, multicenter study is exploring the safety profile, efficacy, and pharmacokinetics of adding daratumumab to venetoclax and dexamethasone with or without bortezomib for patients with relapsed/refractory multiple myeloma (RRMM) who have a t(11;14) abnormality. Read More ›

BELLINI was a phase 3, randomized, double-blind, multicenter study designed to investigate the efficacy and safety of venetoclax + bortezomib + dexamethasone versus bortezomib + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Encouraging and well-tolerated treatment efficacy was shown in patients with relapsed/refractory multiple myeloma (RRMM) in this analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) plus dexamethasone and daratumumab or bortezomib. Read More ›

Patients with relapsed/refractory multiple myeloma (RRMM) who have had ≥2 prior lines of therapy, including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI), and who were refractory to pomalidomide and/or an anti-CD38 monoclonal antibody were evaluated in a phase 2 single-arm, multicenter study known as HORIZON. Read More ›